1. Home
  2. ASMB vs HELP Comparison

ASMB vs HELP Comparison

Compare ASMB & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Assembly Biosciences Inc.

ASMB

Assembly Biosciences Inc.

HOLD

Current Price

$26.49

Market Cap

512.1M

Sector

Health Care

ML Signal

HOLD

Logo Cybin Inc. Common Stock

HELP

Cybin Inc. Common Stock

N/A

Current Price

$9.27

Market Cap

504.6M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
ASMB
HELP
Founded
2005
N/A
Country
United States
Canada
Employees
N/A
50
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
512.1M
504.6M
IPO Year
2010
N/A

Fundamental Metrics

Financial Performance
Metric
ASMB
HELP
Price
$26.49
$9.27
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
2
Target Price
$44.20
$51.50
AVG Volume (30 Days)
140.4K
1.6M
Earning Date
05-06-2026
07-01-2026
Dividend Yield
N/A
N/A
EPS Growth
91.78
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$638.39
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$18.50
$3.76
52 Week High
$39.71
$8.55

Technical Indicators

Market Signals
Indicator
ASMB
HELP
Relative Strength Index (RSI) 45.20 69.72
Support Level $21.80 $4.18
Resistance Level $30.36 $8.50
Average True Range (ATR) 1.30 0.52
MACD -0.12 0.01
Stochastic Oscillator 18.77 97.06

Price Performance

Historical Comparison
ASMB
HELP

About ASMB Assembly Biosciences Inc.

Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.

About HELP Cybin Inc. Common Stock

Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.

Share on Social Networks: